Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12895260 | 0.90 | MEN1 (0.35) | HTTSMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL1209503 | 0.90 | MAPT (0.40) | HTTSMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL12895480 | 0.90 | RORC (0.33) | HTTSMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL12895267 | 0.88 | TP53 (0.31) | HTTSMN1; SMN2POLBMAPTALDH1A1 | |
| SCHEMBL12895272 | 0.86 | L3MBTL1 (0.34) | HTTSMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL12895369 | 0.83 | SLC8A1 (0.34) | HTTSMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL14293348 | 0.81 | LMNA (0.38) | SMN1; SMN2LMNAMAPTMEN1KMT2A | |
| SCHEMBL1209183 | 0.81 | ALDH1A1 (0.42) | HTTSMN1; SMN2LMNARAB9ANPC1 | |
| SCHEMBL1209248 | 0.81 | MAPT (0.41) | HTTSMN1; SMN2RAB9ANPC1POLB | |
| SCHEMBL14292980 | 0.81 | MAPT (0.35) | HTTLMNARAB9ANPC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110044938-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | NYCOMED GMBH (DE) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110044938-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | BAX, BCL2, BAD | HTT 798/4885SMN1; SMN2 2135/4885LMNA 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.